The Supreme Court blocked another avenue for product liability litigation against generic drug manufacturers, holding that they cannot be sued for alleged design defect claims “that turn on the adequacy of a drug’s warnings.”
The decision means that plaintiffs will have a tough time bringing any personal injury suits against generic drug makers